Table 2.
Baseline characteristics according to virologic response or non-response to HAART, LEGACY, 2005–2006
| Characteristic | Responders n = 343 | Non-responders n = 181 | P value | ||
|---|---|---|---|---|---|
| Gender (%) | |||||
| Male | 155 | (67.4) | 75 | (32.6) | |
| Female | 188 | (63.95) | 106 | (36.1) | 0.4 |
| Age | |||||
| Years, mean (range) | 9.7 | (0.9–24.8) | 8.0 | (0.05–22.8) | <0.0001 |
| Mode of transmission, n (%) | |||||
| Perinatal | 266 | 63.9 | 150 | 36.1 | 0.3 |
| Behavioral | 55 | (70.5) | 23 | (29.5) | |
| Other/unknown | 22 | (73.3) | 8 | (26.7) | |
| Race/ethnicity | |||||
| Black, non-Hispanic | 216 | (67.9) | 102 | 32.1 | 0.08 |
| Hispanic | 99 | (58.9) | 69 | (41.1) | |
| White non-Hispanic/other/unknown | 28 | (73.7) | 10 | (26.3) | |
| Non-HAART regimens prior to HAART, n (range) | |||||
| Mean | 1.3 | (0–8) | 1.5 | (0–11) | 0.8 |
| Median | 0 | (0–8) | 1 | (0–11) | 0.96 |
| Prophylaxis for PCP | |||||
| Percentage who received prophylaxis | 74.3 | 69.1 | 0.2 | ||
| Baseline CD4 | |||||
| Percent, mean | 22.3 | 23.1 | 0.7* | ||
| Percent, median | 22.0 | 21.2 | 0.7† | ||
| Count (cells/mm3), mean | 699 | 771 | 0.5* | ||
| Count (cells/mm3), median | 456 | 516 | 0.3† | ||
| Nadir CD4 cells | |||||
| Percent, mean‡ | 19.3 | 20.3 | 0.5* | ||
| Percent, median‡ | 19 | 19 | 0.4† | ||
| Count (cells/mm3), mean‡ | 601.2 | 564 | 0.6* | ||
| Count (cells/mm3), median‡ | 378 | 386 | 0.5† | ||
| Viral load | |||||
| Log10 mean (copies/ml) | 4.8 | 4.0 | <0.0001* | ||
| Log10 median (copies/ml) | 4.9 | 4.1 | <0.0001† | ||
*
Test of significance is based on t-distribution with a folded F-test for equality of variances.
†
Test of significance is based on the Wilcoxon Rank Sum Test.
‡
Nadir values available for 371 participants (324 responders, 47 non-responders)